Literature DB >> 21391004

Missing data handling in chronic pain trials.

Yongman Kim1.   

Abstract

In chronic pain trials, proper handling of missing data due to dropout is an important issue because the dropout rate is high and the study conclusion may depend on the method chosen. The intent-to-treat (ITT) principle usually requires imputations for missing data to include the dropouts as well as completers in the statistical analysis. However, a statistical analysis with imputation might lead to a misinterpretation of clinical data. In chronic pain trials, treatment-related dropouts are clinical outcomes themselves. For example, an early dropout due to toxicity usually indicates a treatment failure, as does a dropout due to lack of efficacy. Problems with traditional methods such as last observation carried forward (LOCF) or baseline observation carried forward (BOCF) are identified especially in the chronic pain setting. Alternative methods, such as continuous responder analysis and two-part model analysis, treating dropouts as clinical events, are introduced with an example of osteoarthritis clinical trial data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21391004     DOI: 10.1080/10543406.2011.550112

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  14 in total

1.  Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.

Authors:  Daniel E Falk; Raye Z Litten; Raymond F Anton; Henry R Kranzler; Bankole A Johnson
Journal:  J Stud Alcohol Drugs       Date:  2014-03       Impact factor: 2.582

Review 2.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

3.  The design and conduct of clinical trials to limit missing data.

Authors:  R J Little; M L Cohen; K Dickersin; S S Emerson; J T Farrar; J D Neaton; W Shih; J P Siegel; H Stern
Journal:  Stat Med       Date:  2012-07-25       Impact factor: 2.373

4.  Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury.

Authors:  Sandra Carvalho; Jorge Leite; Felipe Jones; Leslie R Morse; Ross Zafonte; Felipe Fregni
Journal:  Spinal Cord       Date:  2017-12-13       Impact factor: 2.772

Review 5.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

6.  Estimands and missing data in clinical trials of chronic pain treatments: advances in design and analysis.

Authors:  Xueya Cai; Jennifer S Gewandter; Hua He; Dennis C Turk; Robert H Dworkin; Michael P McDermott
Journal:  Pain       Date:  2020-10       Impact factor: 7.926

7.  The BraveNet prospective observational study on integrative medicine treatment approaches for pain.

Authors:  Donald I Abrams; Rowena Dolor; Rhonda Roberts; Constance Pechura; Jeffery Dusek; Sandi Amoils; Steven Amoils; Kevin Barrows; Joel S Edman; Joyce Frye; Erminia Guarneri; Ben Kligler; Daniel Monti; Myles Spar; Ruth Q Wolever
Journal:  BMC Complement Altern Med       Date:  2013-06-24       Impact factor: 3.659

8.  Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.

Authors:  Jonathan N King; Atsushi Hirakawa; Junko Sonobe; Hiroshi Otaki; Nobuhiro Sakakibara; Wolfgang Seewald; Sophie Forster
Journal:  J Vet Sci       Date:  2018-01-31       Impact factor: 1.672

9.  Evaluation of oral robenacoxib for the treatment of postoperative pain and inflammation in cats: results of a randomized clinical trial.

Authors:  Stephen King; Elizabeth S Roberts; Linda M Roycroft; Jonathan N King
Journal:  ISRN Vet Sci       Date:  2012-07-01

10.  Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.

Authors:  G Friton; C Thompson; D Karadzovska; S King; J N King
Journal:  J Vet Intern Med       Date:  2017-05       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.